← All trials
NCT01697007
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2012
- Primary completion
- Dec 1, 2014
- Completion date
- Jun 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 198
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Muhimbili UniversityLead sponsor
- United States ArmyCollaborator
- Swedish Institute for Infectious Disease ControlCollaborator
- Medical Research CouncilCollaborator
- National Institute for Medical Research, TanzaniaCollaborator
- University of LondonCollaborator
- Government of MozambiqueCollaborator
- Ludwig Maximilians UniversityCollaborator
- Mbeya Referral Hospital, TanzaniaCollaborator
- Muhimbili UniversityReponsible party - principal investigator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.